Personalized Ophthalmology Therapies Market Report 2025: $5.46 Bn Opportunities, Trends, Competitive Landscape, Strategies, and Forecasts, 2019-2024, 2024-2029F, 2034F – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Personalized Ophthalmology Therapies Market Report 2025” has been added to ResearchAndMarkets.com’s offering.

The personalized ophthalmology therapies market is experiencing significant growth, with an expected increase from $2.82 billion in 2024 to $3.23 billion in 2025, at a CAGR of 14.4%. This expansion is driven by the rising incidence of diabetes, aging populations, increased demand for precision medicine, and the growing prevalence of ophthalmic diseases. Looking ahead, the market is projected to reach $5.46 billion by 2029, maintaining a CAGR of 14%, fueled by advancements in genetic testing, molecular diagnostics, and increased awareness of personalized medicine.

The future landscape of personalized ophthalmology therapies will be marked by strategic collaborations among biotechnology firms, research institutions, and healthcare providers. Key trends include the integration of artificial intelligence and machine learning, genomics with digital health technologies, genetic and cellular therapies, and advanced technological solutions. These developments are aimed at enhancing treatment efficacy and addressing the chronic nature of vision disorders, often linked to diabetes-related complications like diabetic retinopathy.

Notably, the Centers for Disease Control and Prevention has projected significant increases in diabetic retinopathy and cataract cases if effective interventions aren’t implemented. Leading companies are pushing the boundaries of therapy with innovations like single-dose intravitreal gene therapies, designed to offer prolonged treatment effects while minimizing the need for frequent interventions. A recent highlight includes Sanofi’s SAR446597, which received fast track designation from the US FDA in 2025. This gene therapy targets geographic atrophy in age-related macular degeneration by inhibiting specific complement pathways to slow disease progression.

Major pharmaceutical companies like Novartis are also redefining ocular drug delivery technologies through strategic acquisitions, such as the 2022 acquisition of Kedalion Therapeutics. This move enhances Novartis’ ability to provide precision, patient-centric solutions, solidifying its position in the ophthalmology market.

The market is dominated by players such as Roche Holding AG, Novartis AG, Regeneron Pharmaceuticals Inc., and others, with North America leading in 2024. Meanwhile, the Asia-Pacific region is expected to witness rapid growth. Market reports provide comprehensive insights, with data on global market shares, competitor analysis, and emerging trends, equipping stakeholders with the knowledge needed to navigate this evolving industry.

The market is adjusting to global trade dynamics and tariff shifts, impacting the supply of medical devices and drugs, driving up costs, and causing supply chain challenges. In response, efforts are being made to diversify sourcing, increase local manufacturing, and seek exemptions for critical medical products.

Personalized ophthalmology therapies, leveraging breakthroughs in genomics and biomarker analysis, encompass gene therapy, cell therapy, and tailored drug delivery methods, targeting conditions like AMD, glaucoma, and diabetic retinopathy. These therapies are employed across hospitals, clinics, and research institutes, focusing on optimizing drug selection, dosage, and surgical interventions to enhance patient outcomes.

Report Scope

Markets Covered:

• Therapy Types: Gene Therapy, Cell Therapy, Pharmacogenomics, Targeted Drug Delivery, Other Therapies
• Indications: Age-Related Macular Degeneration, Diabetic Retinopathy, Glaucoma, Retinitis Pigmentosa, Other Indications
• End Users: Hospitals, Specialty Clinics, Research Institutes, Other End Users

Subsegments:

• Gene Therapy: Viral Vector-Based, Non-Viral, CRISPR Gene Editing
• Cell Therapy: Stem Cell, Retinal Pigment Epithelial, iPSC Therapy
• Pharmacogenomics: Drug Response Testing, Genetic Biomarker-Based Therapy, Personalized Drug Dosing
• Targeted Drug Delivery: Nanoparticle-Based, Liposomal, Hydrogel-Based Systems
• Other Therapy Types: RNA-Based, Antisense Oligonucleotide, Peptide-Based Therapy

Key Attributes:

Companies Featured

• Roche Holding AG
• Novartis AG
• Regeneron Pharmaceuticals Inc.
• Alcon Inc.
• Genentech Inc.
• Bausch + Lomb Corporation
• Johnson & Johnson Vision Care Inc.
• Carl Zeiss Meditec AG
• Santen Pharmaceutical Co. Ltd.
• Ocular Therapeutix Inc.
• EyePoint Pharmaceuticals Inc.
• Senju Pharmaceutical Co. Ltd.
• MeiraGTx Ltd.
• Beacon Therapeutics
• Clearside Biomedical Inc.
• Adverum Biotechnologies Inc.
• Ocugen Inc.
• GenSight Biologics
• Nanoscope Therapeutics Inc.
• 4D Molecular Therapeutics Inc.
• Coave Therapeutics.

For more information about this report visit https://www.researchandmarkets.com/r/tg2g1y

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900